Abbott Makes Major Move in Cancer Diagnostics with $21B Exact Sciences Acquisition

Abbott to acquire Exact Sciences for $21 billion, gaining leadership in cancer screening with Cologuard and expanding its diagnostics portfolio into fast-growing oncology segment.